The combination of JAK1/2 inhibitor (ruxolitinib) with either ERK or CSNK2A1 inhibitor had the highest efficacy and lowest toxicity, demonstrating the important role of these targets in AML. This evidence concerns the gene JAK1 and acute myeloid leukemia.